Cyxone AB (CYXO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cyxone AB (CYXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8167
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company develops T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. It also offers cyclotides, a new class of highly specific low toxicity drugs that can be used for several immune-related diseases and cancers. Cyxone also develops biological drugs with pharmacological effects for MS sufferers and RRMS patients. The company also conducts preclinical studies and clinical trials. It operates across Austria and Germany. Cyxone is headquartered in Malmo, Sweden.

Cyxone AB (CYXO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cyxone AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Cyxone Acquires Rights of Rabeximod from Oxypharma 10
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12
Partnerships 13
Cyxone Partners with Medical University of Vienna 13
Cyxone Enters into Agreement with University of Queensland 14
Cyxone Enters into Agreement with Sourcia 15
Cyxone Enters into Agreement with Bachem 16
Cyxone AB – Key Competitors 17
Cyxone AB – Key Employees 18
Cyxone AB – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 17, 2018: Cyxone’s interim report for January-June 2018 20
Feb 16, 2018: Cyxone : Year-end Report 1 January to 31 December 2017 22
Oct 26, 2017: Cyxone: Interim report July 1 to September 30, 2017 23
Aug 30, 2017: Cyxone: Interim report 2017-01-01 to 2017-06-30 24
Clinical Trials 25
Nov 01, 2017: Existing Rabeximod can be used in Cyxone’s planned Phase 2b study in patients with rheumatoid arthritis 25
Other Significant Developments 26
Jun 29, 2018: Cyxone appoints Mangold as market maker 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Cyxone AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cyxone AB, Deals By Therapy Area, 2012 to YTD 2018 8
Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cyxone Acquires Rights of Rabeximod from Oxypharma 10
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12
Cyxone Partners with Medical University of Vienna 13
Cyxone Enters into Agreement with University of Queensland 14
Cyxone Enters into Agreement with Sourcia 15
Cyxone Enters into Agreement with Bachem 16
Cyxone AB, Key Competitors 17
Cyxone AB, Key Employees 18

List of Figures
Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cyxone AB (CYXO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Future Consumer Ltd (FCONSUMER):企業の財務・戦略的SWOT分析
    Future Consumer Ltd (FCONSUMER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Allianz France S.A.:企業の戦略・SWOT・財務情報
    Allianz France S.A. - Strategy, SWOT and Corporate Finance Report Summary Allianz France S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kuwait Petroleum International Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Kuwait Petroleum International Ltd (KPI), a subsidiary of Kuwait Petroleum Corporation, is a downstream energy company. It carries out refining of crude oil, production and marketing of refined petroleum products. The company operates refinery in Milazzo, Italy, and has retail service statio …
  • AIG Japan Holdings Kabushiki Kaisha:企業の戦略・SWOT・財務分析
    AIG Japan Holdings Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report Summary AIG Japan Holdings Kabushiki Kaisha - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Medworxx Inc-医療機器分野:企業M&A・提携分析
    Summary Medworxx Inc (Medworxx), a subsidiary of Aptean Inc is an information technology solution provider that offers software solutions for patient flow, compliance, and education. The company’s software products include patient throughput review software, clinical criteria software, forms and ass …
  • Alphabet Inc:戦略・SWOT・企業財務分析
    Alphabet Inc - Strategy, SWOT and Corporate Finance Report Summary Alphabet Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Japan Petroleum Exploration Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Japan Petroleum Exploration Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Japan Petroleum Exploration Co Ltd (JAPEX) is an oil and gas company that offers exploration, development, production, and sales of oil, natural gas, and other energy resources. The co …
  • Lavendon Group Plc:企業の戦略・SWOT・財務情報
    Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Basin Electric Power Cooperative:企業の戦略・SWOT・財務分析
    Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report Summary Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Morneau Shepell Inc.:企業の戦略・SWOT・財務情報
    Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report Summary Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Club Mediterranee SA:戦略・SWOT・企業財務分析
    Club Mediterranee SA - Strategy, SWOT and Corporate Finance Report Summary Club Mediterranee SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Flowonix Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Flowonix Medical Inc (Flowonix), formerly Medasys Inc is a medical device company that designs and manufactures implantable drug pump to deliver therapeutic drugs into the spine to relieve chronic disorders. The company's products comprise prometra pump, catheter, and accessories and program …
  • Kalvista Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Kalvista Pharmaceuticals Ltd (Kalvista Pharma), formerly Kalvista Limited, is a pharmaceutical company which focuses on the discovery, development and commercialization of small molecule serine protease inhibitors. It develops a proprietary portfolio of small molecule plasma kallikrein inhib …
  • Walmart Chile S.A.:企業の戦略的SWOT分析
    Walmart Chile S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Nimir Industrial Chemical Ltd (NICL):企業の財務・戦略的SWOT分析
    Summary Nimir Industrial Chemical Ltd (NICL) is a chemical company that manufactures and distributes oleo chemicals and chlor alkali. The company offers products such as stearic acid, soap noodles, glycerin, caustic soda, sodium hypochlorite, and hydrochloric acid, among others. It also provides raw …
  • Vaisala oyj (VAIAS):企業の財務・戦略的SWOT分析
    Summary Vaisala oyj (Vaisala) is a manufacturer of industrial and environmental measurement products. Its products include automatic weather stations and sensors, aviation weather systems, wireless temperature and humidity data loggers, indoor monitoring systems, weather radar products, rail weather …
  • The Dai-ichi Life Insurance Co Ltd:戦略・SWOT・企業財務分析
    The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Dai-ichi Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Maruho Co Ltd:企業の戦略的SWOT分析
    Maruho Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Tootsie Roll Industries, Inc.:企業の戦略・SWOT・財務情報
    Tootsie Roll Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tootsie Roll Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆